CAPR Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 10.87%, SMA50 8.65%, SMA200 113.05%). The stock’s 14-day RSI is 59.98 (neutral), while the ATR of 1.68 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -30.91% below its high and over 548.6% above its low. Average 10-day trading volume of 2.65 million shares is below the 3-month average of 6.35 million, indicating normal recent market interest.

Capricor Therapeutics, Inc. has 58.14 million shares outstanding. The public float is 45.55 million shares, elevated short interest at 30.49% of float. This equals 15.98 million shares. The short ratio is 3.28 days. Institutional investors hold 65.9% of the float. Insiders own 9.47%. Nippon Shinyaku Co Ltd holds 7.09 million shares, CEDARS SINAI MEDICAL CENTER has 4.05 million shares and TANEN DAVID M has 1.52 million shares. Over the past six months, insider transactions show net selling. They sold 271.53 thousand shares across 11 transactions.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) closed at $8.81 USD, gaining $0.44 (5.26%) from the previous close of $8.37. The stock is currently mid-range between its 52-week high and low $2.96 and $40.37. With a market capitalization of about $506.67 million, Capricor Therapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.53). Key stats such as the average daily volume over the past year has been around 6.34 million shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, Capricor Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Linda Marbán, the company employs approximately 231 people and listed since February 13, 2007. Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs.

Capricor Therapeutics, Inc. generated EPS of -$1.80 over the past year. Five-year average earnings growth is 11.01%. The latest quarter delivered EPS of -$0.70. The next quarter is forecast at -$0.51. Next year's EPS is expected at -$2.81. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 10 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $63.00 to $2.00. The high target offers 615.1% upside. The low target suggests -77.3% downside. The mean target is $40.53. This offers 360.05% upside. Capricor Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 14, 2026, missed forecasts by 18.87%. The prior quarter beat by 18.87%. Over the last six quarters, Apple has recorded several small beats. These include 18.75% in August 11, 2025.

Capricor Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $5.81. This means the shares are trading above this model’s fair value.

Capricor Therapeutics, Inc. trades at a P/E ratio of -3.58, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.06 suggesting the stock is closer to book value. The P/FCF stands at -3.89, also below market averages.

Our AI price prediction model suggests that Capricor Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.72%, with price expected at $9.05 by September 28, 2026, within a range of $5.51 to $12.59 3-Month Outlook: Projected rise of 224.74%, reaching $28.61 by December 10, 2026, with a range of $27.29 to $29.96. 1-Year Outlook: Projected gain of 178.21%, with price at $24.51 by September 14, 2027, within a range of $19.16 to $33.17.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares are down -16.15% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Capricor Therapeutics, Inc. trading at a premium to the broader market with a P/E of -3.58. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $35.50, suggesting 302.95% upside. Our AI forecast model points to short-term strength (2.72% over two weeks), a medium-term rise (224.74% over three months), and a longer-term gain (178.21% over one year), with expected trading ranges indicating moderate volatility.